News

Novo Nordisk to Replace C.E.O. After Losing Edge in Weight-Loss Drugs
The Danish drugmaker, which makes Ozempic and Wegovy, has seen its stock tumble as competition in the weight-loss drug market ...
Novo Nordisk and Septerna Strike $2.2 Billion Deal to Develop Obesity Pills
The deal with U.S. biotech Septerna will see the companies develop pills to treat obesity, type 2 diabetes and other ...
Novo Nordisk Says Its 'Wegovy In A Pill' Delivers Big: '16.6% Average' Weight Loss, Over 20% For One-Third Of Adults Struggling With Obesity
Novo Nordisk A/S (NYSE: NVO) is seeking FDA approval for the pill version of its obesity drug, Wegovy. The company highlights ...
Indianapolis Business Journal4d
Novo Nordisk inks $2.2B deal to develop weight-loss pill to rival Lilly’s orforglipron
Indianapolis-based Eli Lilly & Co. announced promising results from a large study of its own tablet in diabetes patients last ...
Wall Street Journal26d
Novo Nordisk Shares Fall After Data From New Eli Lilly Pill
Novo Nordisk NOVO.B-0.63%decrease; red down pointing triangle shares fell Tuesday after Eli Lilly LLY-1.26%decrease; red down pointing triangle announced results of a new pill that could rival ...
Novo Nordisk announces CEO transition as share price slips
After nearly tripling the company’s value, CEO Lars Fruergaard Jørgensen is preparing to exit amid boardroom shifts. Novo Nordisk announced Friday that it would part ways with its longtime CEO, who ...